BOSTON, Sept. 4, 2025 /PRNewswire/ — Holly Polglase, a seasoned litigator with extensive experience in the defense and trial of complex product liability, toxic tort, general liability and commercial matters, has joined Shook, Hardy & Bacon as a partner in the Boston office.
Polglase has represented major national and multinational companies across the supply chain, including product manufacturers and the companies that service them, in the automotive, pharmaceutical and medical device industries, among many others.
“We’ve worked with Holly extensively over the years, making her addition not just an important strategic expansion of our capabilities in Boston and the Northeast, but a natural fit,” said Paul Williams, co-chair of Shook’s General Liability Litigation Practice.
“Holly’s technical knowledge and trial experience, her ability to creatively solve problems and our longstanding relationship make her a compelling addition to the firm,” said Shook Chair Madeleine McDonough.
“This is a great opportunity to join a firm I’ve long admired and to work with lawyers I’ve counted as friends throughout my career,” said Polglase.
Also joining with Polglase is Senior Counsel Matthew Bown, who has extensive experience in product liability and commercial litigation matters for large and small companies in a range of industries.
About Shook, Hardy & Bacon
Founded in 1889, Shook, Hardy & Bacon L.L.P. has 18 offices in the United States with attorneys and professional staff serving clients in the health, science and technology sectors in areas ranging from product liability defense and business litigation to intellectual property prosecution and litigation, environmental and toxic tort, privacy and data security and regulatory counseling.
SOURCE Shook, Hardy & Bacon L.L.P.
New multilingual capabilities expand access to real-time GLP-1 dining guidance as WHO highlights the importance…
ATLANTA, GA AND DOHA, QATAR / ACCESS Newswire / December 6, 2025 / Ameerex Corporation…
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…